Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim Limited

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

39 comunicati stampa

Guarda tutti i comunicati
26/02/2026
Farmaceutica
Medicina Salute Benessere
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
13/01/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
12/01/2026
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
19/12/2025
Farmaceutica
Medicina Salute Benessere
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
28/11/2025
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim announces appointment to Board of Managing Directors
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
04/11/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmaceutica
Pubblicità/Marketing/Media/Comunicazione
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Fonte
Boehringer Ingelheim Limited
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0